AFT Pharmaceuticals (NZSE:AFT) Total Current Liabilities: NZ$66.3 Mil (As of Mar. 2026)


NZSE:AFT AFT Pharmaceuticals Ltd NZSE:AFT
95 GF Score
Price NZ$3.70
GF Value NZ$4.16
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Total Current Liabilities?

AFT Pharmaceuticals NZSE:AFT +0.82% 95 Total Current Liabilities is NZ$66.3 Mil as of Mar. 2026. GuruFocus rates NZSE:AFT with a GF Score™ of 95/100 and a GF Value™ of NZ$4.16 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. AFT Pharmaceuticals's total current liabilities for the quarter that ended in Mar. 2026 was NZ$66.3

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

AFT Pharmaceuticals Total Current Liabilities Related Terms

AFT Pharmaceuticals Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Total Current Liabilities Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.05 39.78 46.07 43.26 66.35

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.07 31.92 43.26 70.76 66.35
NZSE:AFT
95GF Score
AFT Pharmaceuticals Ltd NZSE:AFT
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

AFT Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=39.218+12.513
+Other Current Liabilities+Current Deferred Liabilities
=7.576+7.04
=66.3

AFT Pharmaceuticals's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=39.218+12.513
+Other Current Liabilities+Current Deferred Liabilities
=7.576+7.04
=66.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of NZ$66.3 Mil mean?
AFT Pharmaceuticals (NZSE:AFT) has a Total Current Liabilities of NZ$66.3 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for AFT Pharmaceuticals and its competitors.
Is AFT Pharmaceuticals' Total Current Liabilities too high?
AFT Pharmaceuticals' current Total Current Liabilities is NZ$66.3 Mil. Overall, AFT Pharmaceuticals has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Total Current Liabilities compare to ZTS and UTHR?
AFT Pharmaceuticals' Total Current Liabilities of NZ$66.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for AFT Pharmaceuticals and its competitors. AFT Pharmaceuticals's current Total Current Liabilities is NZ$66.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$4.16, compared to a current price of NZ$3.70 — trading 11.1% below its estimated fair value. The current Total Current Liabilities is NZ$66.3 Mil. AFT Pharmaceuticals' overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current Total Current Liabilities is NZ$66.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of NZ$3.70 is trading 11.1% below its estimated GF Value™ of NZ$4.16. GuruFocus considers AFT Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NZSE:AFT:

  • Total Current Liabilities: NZ$66.3 Mil
  • GF Value™: NZ$4.16 vs. price of NZ$3.70 (11.1% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFT Pharmaceuticals Business Description

Other Exchanges AFP:Australia
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
95GF Score

Get the complete analysis for NZSE:AFT

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$3.70
Price
NZ$4.16
GF Value